Compare CXDO & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXDO | ELUT |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.9M | 42.5M |
| IPO Year | 1999 | 2020 |
| Metric | CXDO | ELUT |
|---|---|---|
| Price | $5.79 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $9.20 | $6.00 |
| AVG Volume (30 Days) | ★ 263.7K | 49.2K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 166.67 | 146.77 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $68,167,000.00 | $12,293,000.00 |
| Revenue This Year | $45.26 | N/A |
| Revenue Next Year | $13.31 | $10.83 |
| P/E Ratio | $116.20 | ★ N/A |
| Revenue Growth | ★ 12.05 | N/A |
| 52 Week Low | $5.54 | $0.50 |
| 52 Week High | $11.23 | $1.39 |
| Indicator | CXDO | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.58 |
| Support Level | N/A | $0.80 |
| Resistance Level | N/A | $1.01 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 22.35 |
Crexendo Inc is a software technology company that provides cloud communication platform software and unified communications as a service (UCaaS) offering, including voice, video, contact center, and managed IT services. The company operates through two segments: Cloud Telecommunications Services and Software Solutions. Its cloud telecommunications segment generates revenue from the provision of broadband Internet services, managed IT services, software license sales, and infrastructure as a service. The software solutions segment derives revenues from three primary sources: software licenses, software maintenance support and professional services. The majority of the company's revenue is derived from the Cloud Telecommunications Services segment.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.